**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 76693

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Correlation between gut microbiota and glucagon-like peptide-1 in patients with gestational diabetes mellitus**

Liang YY *et al*. Correlation between gut microbiota and GLP-1

Yun-Yi Liang, Ling-Yu Liu, Yan Jia, Yi Li, Jie-Na Cai, Yi Shu, Jing-Yi Tan, Pei-Yi Chen, Hong-Wei Li, Hui-Hua Cai, Xiang-Sheng Cai

**Yun-Yi Liang, Yan Jia, Yi Li, Yi Shu, Jing-Yi Tan, Pei-Yi Chen,** Health Management Center, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan 528000, Guangdong Province, China

**Ling-Yu Liu,** The First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou 450000, Henan Province, China

**Yi Li, Xiang-Sheng Cai,** Shenzhen Hospital, University of Chinese Academy of Sciences, Shenzhen 518001, Guangdong Province, China

**Jie-Na Cai,** Clinical Laboratory, Puning People’s Hospital, Puning 515300, Guangdong Province, China

**Hong-Wei Li,** Institute of Biotherapy, Southern Medical University, Guangzhou 510515, Guangdong Province, China

**Hui-Hua Cai,** Department of Obstetrics and Gynecology, Guangdong Provincial People's Hospital, Guangzhou 510080, Guangdong Province, China

**Author contributions:** Liang YY, Liu LY, and Jia Y designed the study, collected the samples, compiled the data, and drafted and critically revised the manuscript; Li Y, Cai JN, and Shu Y compiled the data and performed the statistical analysis and data interpretation; Tan JY collected the samples and compiled the data; Chen PY critically revised the manuscript; Cai HH and Cai XS designed this study, collected the samples, and drafted and critically revised the manuscript; all authors contributed to the article and approved the submitted version.

**Supported by** the National Natural Science Foundation of China, No. 81701396; Foshan Science and Technology Planning Project, No.1920001001163; and Shenzhen Guangming District Soft Science Research Project, No. 2021R01002.

**Corresponding author: Xiang-Sheng Cai, MD, PhD, Associate Professor,** Shenzhen Hospital, University of Chinese Academy of Sciences, No. 4253 Songbai Road, Guangming District, Shenzhen 518001, Guangdong Province, China. xiangshengcai@yeah.net

**Received:** March 26, 2022

**Revised:** June 25, 2022

**Accepted:** August 24, 2022

**Published online:** October 15, 2022

**Abstract**

BACKGROUND

Gestational diabetes mellitus (GDM) places both the mother and offspring at high risk of complications. Increasing evidence suggests that the gut microbiota plays a role in the pathogenesis of GDM. However, it is still unclear whether the gut microbiota is related to blood biochemical traits, particularly glucagon-like peptide-1 (GLP-1), in GDM patients.

AIM

To explore the correlation between the gut microbiota and blood biochemical traits, particularly GLP-1, in GDM patients.

METHODS

The V4 region of the 16S ribosomal ribonucleic acid (rRNA) gene was sequenced based on the fecal samples of 35 pregnant women with GDM and was compared to that of 25 pregnant women with normal glucose tolerance (NGT).

RESULTS

The results showed that *Ruminococcaceae\_UCG-002*, *Ruminococcaceae\_UCG-005*, *Clostridium\_sensu\_stricto\_1*,and *Streptococcus* were more abundant in the NGT group than in the GDM group*. Bacteroides* and *Lachnoclostridium* were more abundant in the GDM group than in the NGT group.Spearman’s correlation analysis was performed to identify the relationships between microbiota genera and blood biochemical traits. *Paraprevotella*, *Roseburia*, *Faecalibacterium*, and *Ruminococcaceae\_UCG-002* were significantly negatively correlated with glucose. *Ruminococcaceae\_UCG-002* was significantly negatively correlated with hemoglobin A1c. *Bacteroides* was significantly positively correlated with glucose. *Sutterella*, *Oscillibacter*,and *Bifidobacterium* were significantly positively correlated with GLP-1. A random forest model showed that 20 specific genera plus glucose provided the best discriminatory power, as indicated by the area under the receiver operating characteristic curve (0.94).

CONCLUSION

The results of this study reveal novel relationships between the gut microbiome, blood biochemical traits, particularly GLP-1, and GDM status. These findings suggest that some genera are crucial for controlling blood glucose-related indices and may be beneficial for GDM treatment. Alteration in the microbial composition of the gut may potentially serve as a marker for identifying individuals at risk of GDM.

**Key Words:** Gut microbiome; Glucagon-like peptide-1; Gestational diabetes mellitus; Glucose

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Liang YY, Liu LY, Jia Y, Li Y, Cai JN, Shu Y, Tan JY, Chen PY, Li HW, Cai HH, Cai XS. Correlation between gut microbiota and glucagon-like peptide-1 in patients with gestational diabetes mellitus. *World J Diabetes* 2022; 13(10): 861-876

**URL**: https://www.wjgnet.com/1948-9358/full/v13/i10/861.htm

**DOI**: https://dx.doi.org/10.4239/wjd.v13.i10.861

**Core Tip:** Increasing evidence suggests that the gut microbiota plays a role in the pathogenesis of gestational diabetes mellitus (GDM). However, it is still unclear whether the gut microbiota is related to blood biochemical traits, particularly glucagon-like peptide-1 (GLP-1), in GDM patients. To the best of our knowledge, this is the first study to analyze the relationship between GLP-1 and the gut microbiota in patients with GDM, and this is the first report on the relationship between *Paraprevotella*, *Roseburia*, and *Faecalibacterium* and glucose in GDM, and the first report on the associations between GLP-1 and genera including *Sutterella, Oscillibacter*, and *Bifidobacterium* in GDM.

**INTRODUCTION**

Gestational diabetes mellitus (GDM) is defined as abnormal glucose tolerance in pregnancy[1]. It is one of the most common complications of pregnancy. The incidence of GDM has increased due to lifestyle changes, increasing maternal age, and changes to the GDM diagnostic criteria. The incidence of GDM is reported to be 13.20%. GDM is closely related to the occurrence of perinatal maternal and neonatal complications, and also significantly increases the risk of long-term metabolic diseases in pregnant women and newborns. The pathogenesis of GDM is complex and has not yet been comprehensively elucidated. Timely diagnosis and intervention are of great significance to the long-term health of pregnant women and their fetuses.

In recent years, with increased research and understanding of gastrointestinal hormones, their roles in the occurrence and development of GDM have attracted growing attention. Research suggests that GDM patients exhibit insufficient glucagon-like peptide-1 (GLP-1) secretion during pregnancy and after delivery relative to their blood glucose level. Bonde *et al*[[2](#_ENREF_2)] found that the postprandial GLP-1 level of pregnant women was decreased, especially in GDM patients. However, with the recovery of blood glucose homeostasis after delivery, postprandial GLP-1 secretion gradually returned to normal. Kosinski *et al*[[3](#_ENREF_3)] confirmed that decreased GLP-1 in patients with GDM is reversible. Changes in GLP-1 levels may be related to insulin resistance (IR) as a result of high blood glucose levels. However, it cannot be ruled out that changes in GLP-1 levels may be involved in the occurrence and development of GDM.

Evidence indicates that the gut microbiota is closely related to GDM[[4](#_ENREF_4" \o "Huang, 2021 #7)]. The mechanism underlying the effect of probiotics in diabetes has not yet been fully elucidated, but it may be related to reductions in oxidative stress, regulation of the immune response, reductions in inflammation, and regulation of the gut microbiota[[5](#_ENREF_5),[6](#_ENREF_6)]. In addition, probiotics can also reduce postprandial blood lipid levels and improve the absorption of antioxidants, which are related to oxidative stress[[7](#_ENREF_7)]. Numerous studies have demonstrated that GLP-1 has insulin tropic and antioxidant effects[[8-10](#_ENREF_8)]. Since GLP-1 and the gut microbiota each play roles in GDM, is there a correlation between the two?

Both clinical and animal studies have reported correlations between changes in the GLP-1 level and changes in the gut microbiota after gastrointestinal bypass surgery in type 2 diabetes mellitus (T2DM) patients or mice[[11](#_ENREF_11)]. Therefore, it is speculated that GLP-1 may regulate blood glucose by regulating the number and structure of gut microbiota. Several authors have argued that GLP-1 may play a role in regulating blood glucose by increasing the diversity of the gut microbiota[[12](#_ENREF_12)] and increasing the proportion of probiotics. Together, the current literature provides a comprehensive explanation of the hypoglycemic mechanism of GLP-1 and a reliable experimental basis for the study of GDM therapeutic targets and therapeutic drugs based on GLP-1. Accordingly, one study found that bifidobacteria improved insulin sensitivity by increasing the production of GLP-1[[13](#_ENREF_13)].

The rapid increase in the prevalence of GDM in recent years cannot be easily explained by genetic factors; thus, it has been hypothesized that environmental factors may play a more important role. The gut microbiota constitutes an important environmental factor. GLP-1, as the most important representative of gastrointestinal hormones, may also be involved in the pathogenesis of GDM. The gastrointestinal microbiota and gastrointestinal hormones share the same root, are inseparable, influence and restrict each other, and jointly participate in the occurrence, development, and prognosis of GDM. Thus, a comprehensive study of the correlations between changes in the gut microbiota and GLP-1 will help to further clarify the pathogenesis of GDM. This is of great significance for the prevention, treatment, and prognosis of GDM, and may provide a novel and sensitive index for the clinical evaluation of GDM.

**MATERIALS AND METHODS**

***Subjects***

Patients were screened for GDM in the obstetric outpatient department according to the GDM diagnostic criteria (2014). Thirty-five patients with GDM were randomly selected from the patients who met the diagnostic criteria for GDM; these patients formed the GDM group. A further 25 pregnant women with normal glucose tolerance (NGT) were selected as the NGT group. Each subject provided written informed consent before inclusion in the study. The study was approved and carried out in accordance with the guidelines of the Ethics Committee of Nanhai District People’s Hospital of Foshan.

The inclusion criteria were as follows: 18-45 years old, being female, and any education level. Based on the diagnostic criteria for gestational diabetes (2014), during the 24-28th week of gestation, the 75 g oral glucose tolerance test (OGTT) was used to measure each patient’s blood glucose levels before, 1 h after, and 2 h after consuming sugar. If the patient’s blood glucose level reached or exceeded 5.1, 10.0, or 8.5 mmol/L, respectively, they were deemed to have GDM and were eligible for inclusion in the GDM group.

The exclusion criteria were as follows: (1) History of chronic digestive system disorder; (2) history of treatment with GLP-1 analogues or GLP-1 receptor agonists; (3) history of cardiac, renal, or liver dysfunction; (4) multiple pregnancy; (5) pregnancy-induced hypertension syndrome, placental insufficiency, placenta previa, placental abruption, pelvic or soft birth canal abnormalities, or other pregnancy complications; (6) history of mental disorders; (7) exposure to a large amount of radiation, chemical poisons, or drugs that can affect the fetus during pregnancy; (8) tumor history or history of radiotherapy and chemotherapy within the past 6 mo; (9) participation in other research studies; (10) patients lost to follow-up due to various reasons, including the occurrence of other serious diseases during the study; and (11) consumption of antibiotics or probiotics within 1 mo prior to admission.

***Sample collection and testing***

Fresh fecal samples were collected from the participants and immediately frozen in a refrigerator at -80 °C. After collection of all samples, they were sent to the Treat Gut company for 16S rDNA sequencing.

Blood samples were collected after fasting and then 1 h and 2 h following consumption of sugar. Plasma glucose (Glu), glycosylated serum protein (GSP), low-density lipoprotein (LDL), uric acid (UA), hemoglobin (HB), total cholesterol (TCH), triglyceride (TG), and high-density lipoprotein (HDL) were determined with a Beckman AU5800 fully automatic biochemical analyzer. Glycosylated hemoglobin A1c (HbA1c) was determined using an ADAMS™ A1c HA-8180 automatic glycosylated hemoglobin analyzer. Insulin (INS), thyroid-stimulating hormone (TSH), and free tetraiodothyronine (FT4) were measured with a Maglumi2000plus automatic chemiluminescence immunoanalyzer.

The active forms of GLP-1 in the plasma samples of patients with and without GDM were measured using a GLP-1 (active) ELISA kit (ELabscience, Wuhan, Hubei Province, China).

***Bacterial 16S rRNA gene sequencing***

The total genomic DNA of each sample was extracted using a fecal genomic DNA extraction kit (Tiangen Company). Sixteen S rDNA sequencing was performed by PCR amplification of V4 variable regions (39 to 297 base pairs), and a purified product library was established. The library construction steps followed the library construction method of the Illumina sequencing platform. The sequencing analysis was as follows. First, the Illumina Miseq 2 × 300bp paired-end sequencing data were analyzed. According to the barcode information, the samples were distinguished. Then, the data were merged, spliced, and filtered, and quality control analysis was conducted, including Q20 and Q30 scores. The final clean data were analyzed by operational taxonomic unit (OTU) cluster analysis and species taxonomy.

***Microbiome data***

The data were filtered using Mothur software and clustered into OTUs (species) at a similarity level of 97% using Quantitative Insights into Microbial Ecology (QIIME) software version 1.80[14]. Based on the OTU analysis, the Ace, Shannon, observed species, Simpson, Chao1, and J indices were calculated as alpha diversity metrics. To compare the microbial composition between the samples, beta diversity analysis was performed using principal component analysis (PCA) and principal coordinate analysis (PCoA). Analysis of similarities (ANOSIM) was applied to evaluate the statistical significance of differences between the groups. A linear discriminant analysis (LDA) effect size (LEfSe) method was employed to evaluate any differences in the gut microbe between the groups.

***Statistical analysis***

GraphPad Prism (version 7.0) and R version 3.0.2 (R Foundation for Statistical Computing) were using for statistical analyses. The measurement data are expressed as the mean ± SD. Differences between groups were analyzed using one‑way ANOVA. The differences were considered statistically significant at *P* < 0.05. Random-forest classification was performed for discriminating the samples from different groups using the R package “random forest”. The model was employed for five-fold cross-validation of the relative species abundance profile. Case probabilities were calculated by drawing receiver operating characteristic (ROC) curves.

**RESULTS**

***Characteristics of the study population***

GDM was diagnosed in 35 women based on fasting or oral glucose-stimulated hyperglycemia, or a combination of the two. Markers of glucose and insulin homeostasis were higher in the GDM group compared with the NGT group (Table 1). Individuals with GDM also had higher hemoglobin A1C (*P* = 0.003) and fasting blood glucose levels (*P* <0.001). There were no significant differences in pre-pregnancy body weight, BMI, UA, TCH, TG, HDL, LDL, TSH, or FT4 between the two groups.

***OTU distributions***

In this study, the OTUs annotated included 14 phyla, 62 families, and 214 genera of gut microbiota; the similarity among samples was 97% (Figure 1A). The total number of OTUs of the NGT group (at the 97% similarity level) was 652, and for the GDM group, it was 619. Venn diagram shows that 560 OTUs were shared by the NGT and GDM groups (Figure 1B).

***Alpha and beta diversities***

The observed species index of the GDM group was significantly difference from that of the NGT group (25; *P* = 0.044). The Chao1 richness index of the GDM group was significantly different from that of the NGT group (43; *P* = 0.004). The ACE index of the GDM group differed significantly from that of the NGT group (25; *P* = 0.0055) (Figure 2). There were no significant differences in the Shannon, Simpson, or J indices between the GDM group and NGT group (Shannon, *P* = 0.65; Simpson, *P* = 0.9; J, *P* = 0.91; Figure 2A). PCA and PCoA indicated that the gut microbiota in GDM patients differed significantly from that of the NGT subjects. There was no difference in the gut microbiota structure between the groups (ANOSIM, *r* = 0.019, *P* = 0.2232). NMDS cluster analysis indicated marked differences between the GDM patients and NGT subjects (Figure 2B).

***Taxonomy***

The composition of gut microbiota was different between the groups at the phylum, family, and genus levels. At the phylum level, *Bacteroidetes*, *Proteobacteria*, *Firmicutes*, *Verrucomicrobia*, *Actinobacteria*, *Fusobacteria*, *Synergistetes*,and *Tenericutes* were common phyla in both the GDM group and NGT group, accounting for 98.81% and 98.58% of the gut bacteria of each group, respectively (Figure 3). The GDM group had a lower abundance of *Firmicutes* (31.4% *vs* 33.2%), *Verrucomicrobia* (0.18% *vs* 1.01%, *P* <0.05), *Synergistetes* (0.003% *vs* 0.110%, *P* <0.01), and *Tenericutes* (0.05% *vs* 0.08%), and a higher abundance of *Bacteroidetes* (63.50% *vs* 60.81%), *Proteobacteria* (3.03% *vs* 2.56%), and *Fusobacteria* (0.33% *vs* 0.29%), compared to the NGT group. The ratio of *Firmicutes* to *Bacteroidetes* was decreased in the GDM group compared to the NGT group (0.49 *vs* 0.54).

At the family level, a greater number of different families were identified between the two groups (Figure 4). Fifty-five and 54 of the dominant families were detected in the GDM group and NGT group, respectively. *Bacteroidaceae* (phylum *Bacteroidetes*), *Prevotellaceae* (phylum *Bacteroidetes*), *Acidaminococcaceae* (phylum *Firmicutes*), *Veillonellaceae* (phylum *Firmicutes)*, *Lachnospiraceae* (phylum *Firmicutes*), *Ruminococcaceae* (phylum *Firmicutes*), *Enterobacteriaceae* (phylum *Proteobacteria*), and *Tannerellaceae* (phylum *Bacteroidetes*) had the highest relative abundance in the GDM group, while *Bacteroidaceae*, *Prevotellaceae*, *Acidaminococcaceae*, *Veillonellaceae*, *Lachnospiraceae*, *Enterobacteriaceae*, *Ruminococcaceae*,and *Rikenellaceae* were the eight most abundant families in the NGT group.

The bacterial taxa whose levels differed significantly between the two groups were identified by LEfSE analysis (Figure 4). At the family level, *Atopobiaceae*, *Eggerthellaceae*, *Streptococcaceae*, *Christensenellaceae*, *Clostridiaceae*, *Bifidobacteriaceae*, *Lachnospiraceae*, and *Ruminococcaceae* were significantly more abundant in the NGT group than in the GDM group.

At the genus level, bacterial genera exhibited significant differences between the two groups (Figure 5). In the NGT group, *Bacteroides* (phylum *Bacteroidetes*), *Prevotella\_9* (phylum *Bacteroidetes*), *Phascolarctobacterium* (phylum *Firmicutes*), *Megasphaera* (phylum *Firmicutes*), *Megamonas* (phylum *Firmicutes*), *Lachnospiraceae* (phylum *Firmicutes*), *Escherichia-Shigella* (phylum *Proteobacteria*), and *Prevotella\_2* (phylum *Bacteroidetes*) were the eight most dominant genera. The eight most dominant genera in the GDM group were *Bacteroides* (phylum *Bacteroidetes*), *Prevotella\_9* (phylum *Bacteroidetes*), *Megamonas* (phylum *Firmicutes*), *Phascolarctobacterium* (phylum *Firmicutes*), *Lachnospiraceae* (phylum *Firmicutes*), *Megasphaera* (phylum *Firmicutes*), *Prevotella\_2* (phylum *Bacteroidetes*), and *Parabacteroides* (phylum *Bacteroidetes*).

*Ruminococcaceae\_UCG-002*, *Ruminococcaceae\_UCG-005*, *Clostridium\_sensu\_stricto\_1,* and *Streptococcus* were more abundant in the NGT group than in the GDM group (*P* <0.05). *Bacteroides* and *Lachnoclostridium* were more abundant in the GDM group than in the NGT group (*P* <0.05). *Prevotella\_9*, *Oscillibacter*, *Roseburia*,and *Faecalibacterium* were slightly more abundant in the NGT group than in the GDM group.

***Functional profiling of the gut microbiome***

The cluster of orthologous groups (COG) categories and KEGG pathways were compared between the GDM and NGT groups. Figure 6A shows that three functional KEGG pathways differed between the GDM group and NGT group, including the glycosphingolipid biosynthesis-globo series, synthesis and degradation of ketone bodies, and renal cell carcinoma pathways. Figure 6B shows that 20 COG categories differed between the GDM group and NGT group, including the phosphotransferase system, galactitol-specific IIC component, metal-dependent proteases with possible chaperone activity, uncharacterized protein, homolog of phage Mu protein gp30, uncharacterized protein conserved in bacteria, Acyl-CoA dehydrogenases, putative virion core protein (lumpy skin disease virus), predicted phosphohydrolase, large-conductance mechanosensitive channel, uncharacterized conserved protein, uncharacterized protein predicted to be involved in DNA repair, predicted permease, DMT superfamily, nicotinic acid mononucleotide adenylyltransferase, amidases related to nicotinamidase, histone acetyltransferase, plasmid maintenance system antidote protein, uncharacterized conserved protein, DNA polymerase III, alpha subunit, uncharacterized protein conserved in bacteria, antirestriction protein, NA polymerase III, and alpha subunit (Gram-positive type).

***Correlations between blood biochemical traits and gut composition***

Spearman’s correlation analysis was performed to identify whether the different dominant genera were associated with blood biochemical traits in the second trimester of pregnancy (Figure 7). *Paraprevotella*, *Roseburia*, *Faecalibacterium*, and *Ruminococcaceae\_UCG-002* were negatively correlated with Glu (*P* <0.05). *Ruminococcaceae\_UCG-002* was negatively correlated with HbA1c (*P* <0.05). *Clostridium\_sensu\_stricto\_1*, *Desulfovibrio*,and (*Ruminococcus*)*\_torques\_group* were negatively correlated with pre-pregnancy body weight (*P* <0.05). *Phascolarctobacterium* was negatively correlated with HDL (*P* <0.05). *Ruminococcaceae\_UCG-003* and *Faecalibacterium* were negatively correlated with height (*P* <0.05). *Lachnoclostridium* and *Lachnospiraceae\_NK4A136\_group* were positively correlated with age (*P* <0.05). *Bacteroides* was significantly positively correlated with Glu (*P* <0.01). *Sutterella*, *Oscillibacter*,and *Bifidobacterium* were positively correlated with GLP-1 (*P* <0.05).

*Roseburia* was negatively correlated with OGTT (0 h), OGTT (1 h), and OGTT (2 h) (*P* <0.05). *Faecalibacterium* was negatively correlated with OGTT (0 h) and OGTT (1 h) (*P* <0.05). *Bacteroides* was positively correlated with OGTT (0 h), OGTT (1 h), OGTT (2 h), and GSP (*P* <0.05). *Lachnoclostridium* was positively correlated with OGTT (1 h) and OGTT (2 h) (*P* <0.05). *Sutterella* was positively correlated with GLP-1(0 h), GLP-1(1 h), GLP-1(2 h), and pre-pregnancy BMI (*P* <0.05). *Oscillibacter* was positively correlated with GLP-1(0 h), GLP-1(1 h), and GLP-1(2 h) (*P* <0.05). *Bifidobacterium* was positively correlated with GLP-1(0 h), GLP-1(1 h), OGTT (2 h), TG, and TCH (*P* <0.05).

***Gut microbiota–based prediction of GDM***

Finally, random forest models were used to assess the ability of the genera abundance profiles to predict GDM status (Figure 8A). Twenty genera plus Glu provided the best discriminatory power, as indicated by the area under the receiver operating characteristic (AUROCC) value of 0.94. The value was higher than that achieved with a model including just 20 genera (the best AUC was 0.828) (Figure 8B). Further, models with 20 genera plus GLP-1, INS, or HbA1c had lower AUROCC values than the model with 20 genera plus Glu. The AUROCC values were 0.81, 0.8288, and 0.8502, respectively.

**DISCUSSION**

In recent years, the relationships between the gut microbiota and diabetes as well as other endocrine diseases have become research hotspots. Similarly, the characteristics of the gut microbiota among pregnant women with GDM have received widespread research attention. To date, research on GDM has focused on the correlation between the gut microbiota and blood glucose or insulin, but there is still a lack of research on the relationship between the gut microbiota and GLP-1. Many studies have reported that GLP-1 is closely related to the gut microbiota and short-chain fatty acids (SCFAs)[[15-17](#_ENREF_14)], and changes in the gut microbiota directly affect the secretion of GLP-1, which, in turn, affects insulin and blood glucose. These are closely related to the occurrence of GDM. Therefore, we focused on the relationship between GLP-1 and the gut microbiota in GDM patients. To the best of our knowledge, it is the first report on the relationship between GLP-1 and the gut microbiota in patients with GDM.

At the phylum level, the abundance of *Firmicutes* in the gut microbiota of the GDM group was lower than that in NGT group. *Firmicutes* are known to transform carbohydrates and undigested proteins into SCFAs, producing energy for the host organism. As a crucial SCFA, butyrate participates in the activation of multiple physiological signal pathways, including the proliferation and differentiation of regulatory T cells and anti-inflammatory activities[[18](#_ENREF_17),[19](#_ENREF_18)]. Moreover, the GDM group exhibited reduced phylum levels of *Verrucomicrobia*, *Synergistetes*,and *Tenericutes* compared to the NGT group. Mucin-degrading bacteria *Verrucomicrobia* contribute to glucose homeostasis and intestinal health, and play a key role in the interaction between the host tissues and gut microbiome[[20](#_ENREF_19)]. The gut microbiota in the GDM patients also exhibited a higher abundance of *Bacteroidetes*, *Fusobacteria,* and *Proteobacteria* compared to healthy subjects. Proteobacteria is an opportunistic pathogen that creates a major structural imbalance in the gut microbiota of GDM patients. The ratio of *Firmicutes t*o *Bacteroidetes* in GDM patients is lower than that of NGT individuals.

At the family level, *Atopobiaceae*, *Eggerthellaceae*, *Streptococcaceae*, *Christensenellaceae*, *Clostridiaceae*, *Bifidobacteriaceae*, *Lachnospiraceae*,and *Ruminococcaceae* were more abundant in the NGT subjects than in the GDM patients. Zhang *et al*[21] reported that *Ruminococcaceae*, *Bifidobacteriaceae*, *Christensenellaceae*, *Erysipelotrichaceae*, *Peptostreptococcaceae*,and *Eggerthellaceae* were more abundant in the NGT subjects, which is consistent with the current study. In line with the study of Ma *et al*[22], the current results revealed that *Ruminococcaceae* were more abundant in the NGT group than in the GDM group. However, other studies have observed the opposite result[[23](#_ENREF_22),[24](#_ENREF_23)]. The mechanisms remain unclear.

At the genus level, *Ruminococcaceae\_UCG-002*, *Ruminococcaceae\_UCG-005*, *Clostridium\_sensu\_stricto\_1*,and *Streptococcus* were more abundant in the NGT group than in the GDM group. *Bacteroides* and *Lachnoclostridium* were more abundant in the GDM group than in the NGT group. Kuang *et al*[[25](#_ENREF_24)] found that the proportion of *Bifidobacterium* in the gut microbiota of GDM pregnant women was significantly reduced, while the proportions of *Bacteroides* and *Klebsiella* were significantly increased. Liu *et al*[26] found that compared with normal pregnant women, the proportion of *Faecalis* in GDM patients was significantly lower, while the proportion of *Prevotella* was significantly higher. In the present study, there were no significant differences in *Bifidobacterium*, *Klebsiella*, or *Prevotella* between the GDM group and NGT group. Ma *et al* found that *Ruminococcaceae\_UCG-002* and *Ruminococcaceae\_UCG-005* were reduced in women with GDM[22].

One study found that supplementation with *Lactobacillus rhamnosus* in pregnant women may reduce the prevalence of GDM[27]. Another study showed that additional probiotic supplementation from pregnancy to 12 months post-delivery can reduce insulin levels and improve insulin sensitivity[28]. In this study, to identify beneficial bacteria for pregnant women, Spearman’s correlation analysis was performed to identify the relationships between bacterial genera and blood biochemical traits. *Paraprevotella*, *Roseburia*, *Faecalibacterium*, and *Ruminococcaceae\_UCG-002* were negatively correlated with Glu. *Ruminococcaceae\_UCG-002* was negatively correlated with HbA1c. *Clostridium\_sensu\_stricto\_1*, *Desulfovibrio*,and(*Ruminococcus*)*\_torques\_group* were negatively correlated with pre-pregnancy body weight. *Phascolarctobacterium* was negatively correlated with HDL. *Ruminococcaceae\_UCG-003* and *Faecalibacterium* were negatively correlated with height. *Lachnoclostridium* and *Lachnospiraceae\_NK4A136\_group* were positively correlated with age. Zhang *et al*[[21](#_ENREF_21)]found that *Ruminococcaceae\_UCG-002* was negatively correlated with fasting blood glucose levels. In the study of Crusell, *Clostridium (sensu stricto)* was positively correlated with gestational weight[[29](#_ENREF_26)]. To the best of our knowledge, no studies have yet reported on the relationships between *Paraprevotella*, *Roseburia*,and *Faecalibacterium* and Glu in GDM. The current findings suggest that these genera are crucial for controlling blood glucose-related indices and may be beneficial for GDM treatment.

GLP-1 and its receptor agonist can promote insulin secretion only when the blood glucose level is elevated[30]. This safety feature makes GLP-1 and its agonist suitable for the treatment of GDM, which requires strict maintenance of blood glucose levels and stable, safe blood glucose regulation. Thus, the current study aimed to examine the correlations between the gut microbiota and GLP-1 levels, and identify beneficial bacteria that can improve the expression of GLP-1 in patients with GDM, so as to more safely control blood glucose. In the present study, *Sutterella* was significantly positively correlated with GLP-1 (0 h), GLP-1 (1 h), GLP-1 (2 h), and pre-pregnancy BMI*.* Wang *et al*[[31](#_ENREF_28)]reported that subjects taking metformin exhibited a significantly increased relative abundance of *Sutterella*, whereas liraglutide dosing was associated with a significant increase in the genus *Akkermansia*. Another study showed that *Sutterella* was associated with C-reactive protein levels[[32](#_ENREF_29)]. In the current study, *Oscillibacter* was significantly positively correlated with GLP-1 (0 h), GLP-1 (1 h), and GLP-1 (2 h).One study reported that *Cyclocarya paliurus polysaccharides* alleviated type 2 diabetic symptoms by increasing eleven SCFA-producing species, including *Oscillibacter\_valericigenes* and *Oscillibacter\_ruminantium*[[33](#_ENREF_30)]*. Oscillibacter* belongs to the Clostridia class of Firmicutes, and in the human gut microbiota, this bacterium grow fermentatively, predominantly producing valerate when grown using glucose as a carbon source[[34](#_ENREF_31)]. In the current study, *Bifidobacterium* was significantly positively correlated with GLP-1 (0 h), GLP-1 (1 h), TG, TCH, and OGTT (2 h*).* In the study of Zhao *et al*[[35](#_ENREF_32)], *Bifidobacterium longum DD98* improved the serum and intestinal cell GLP-1 levels, which protected pancreatic β-islet cells from damage induced by type 2 diabetes. To the best of our knowledge, this is the first report on the associations between GLP-1 and genera such as *Sutterella*, *Oscillibacter*, and *Bifidobacterium* in GDM.

**CONCLUSION**

In summary, this study contributes to a better understanding of the relationships between the gut microbiota and blood biochemical traits, particularly GLP-1, in individuals with GDM. The current findings suggest that some genera are crucial for controlling blood glucose-related indices and may be beneficial for GDM treatment. Alteration in the microbial composition of the gut may potentially serve as a marker for identifying individuals at risk of GDM. Future studies combining metagenomics and metabonomics would be of value for improving our understanding of the roles of specific strains and metabolites in patients with GDM and supporting precise prevention and intervention strategies for GDM.

**ARTICLE HIGHLIGHTS**

***Research background***

Gestational diabetes mellitus (GDM) places both the mother and offspring at high risk of complications. Increasing evidence suggests that the gut microbiota plays a role in the pathogenesis of GDM.

***Research motivation***

To confirm whether the gut microbiota is related to blood biochemical traits, particularly glucagon-like peptide-1 (GLP-1), in GDM patients.

***Research objectives***

To explore the correlation between the gut microbiota and blood biochemical traits.

***Research methods***

The V4 region of the 16S ribosomal ribonucleic acid (rRNA) gene was sequenced based on the fecal samples of 35 pregnant women with GDM and was compared to that of 25 pregnant women with normal glucose tolerance (NGT).

***Research results***

The results showed that *Ruminococcaceae\_UCG-002*, *Ruminococcaceae\_UCG-005*, *Clostridium\_sensu\_stricto\_1*,and *Streptococcus* were more abundant in the NGT group than in the GDM group*. Bacteroides* and *Lachnoclostridium* were more abundant in the GDM group than in the NGT group.Spearman’s correlation analysis was performed to identify the relationships between bacterial genera and blood biochemical traits. *Paraprevotella*, *Roseburia*, *Faecalibacterium*, and *Ruminococcaceae\_UCG-002* were significantly negatively correlated with glucose. *Ruminococcaceae\_UCG-002* was significantly negatively correlated with HbA1c. *Bacteroides* was significantly positively correlated with glucose. *Sutterella*, *Oscillibacter*,and *Bifidobacterium* were significantly positively correlated with GLP-1. A random forest model showed that 20 specific genera plus glucose provided the best discriminatory power, as indicated by the area under the receiver operating characteristic curve (0.94).

***Research conclusions***

The results of this study reveal novel relationships between the gut microbiome, blood biochemical traits, particularly GLP-1, and GDM status.

***Research perspectives***

These findings suggest some genera are crucial for controlling blood glucose-related indices and may be beneficial for GDM treatment. Alteration in the microbial composition of the gut may potentially serve as a marker for identifying individuals at risk of GDM.

**REFERENCES**

1 **Feig DS**, Zinman B, Wang X, Hux JE. Risk of development of diabetes mellitus after diagnosis of gestational diabetes. *CMAJ* 2008; **179**: 229-234 [PMID: 18663202 DOI: 10.1503/cmaj.080012]

2 **Bonde L**, Vilsbøll T, Nielsen T, Bagger JI, Svare JA, Holst JJ, Larsen S, Knop FK. Reduced postprandial GLP-1 responses in women with gestational diabetes mellitus. *Diabetes Obes Metab* 2013; **15**: 713-720 [PMID: 23406269 DOI: 10.1111/dom.12082]

3 **Kosinski M**, Knop FK, Vedtofte L, Grycewiczv J, Swierzewska P, Cypryk K, Vilsbøll T. Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus. *Regul Pept* 2013; **186**: 104-107 [PMID: 23958841 DOI: 10.1016/j.regpep.2013.08.002]

4 **Huang L**, Thonusin C, Chattipakorn N, Chattipakorn SC. Impacts of gut microbiota on gestational diabetes mellitus: a comprehensive review. *Eur J Nutr* 2021; **60**: 2343-2360 [PMID: 33512587 DOI: 10.1007/s00394-021-02483-6]

5 **Gomes AC**, Bueno AA, de Souza RG, Mota JF. Gut microbiota, probiotics and diabetes. *Nutr J* 2014; **13**: 60 [PMID: 24939063 DOI: 10.1186/1475-2891-13-60]

6 **Pitocco D**, Di Leo M, Tartaglione L, De Leva F, Petruzziello C, Saviano A, Pontecorvi A, Ojetti V. The role of gut microbiota in mediating obesity and diabetes mellitus. *Eur Rev Med Pharmacol Sci* 2020; **24**: 1548-1562 [PMID: 32096204 DOI: 10.26355/eurrev\_202002\_20213]

7 **Dang F**, Jiang Y, Pan R, Zhou Y, Wu S, Wang R, Zhuang K, Zhang W, Li T, Man C. Administration of Lactobacillus paracasei ameliorates type 2 diabetes in mice. *Food Funct* 2018; **9**: 3630-3639 [PMID: 29961787 DOI: 10.1039/c8fo00081f]

8 **Nyström T**. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. *Horm Metab Res* 2008; **40**: 593-606 [PMID: 18792870 DOI: 10.1055/s-0028-1082326]

9 **Aaboe K**, Krarup T, Madsbad S, Holst JJ. GLP-1: physiological effects and potential therapeutic applications. *Diabetes Obes Metab* 2008; **10**: 994-1003 [PMID: 18435775 DOI: 10.1111/j.1463-1326.2008.00853.x]

10 **Cai X**, She M, Xu M, Chen H, Li J, Chen X, Zheng D, Liu J, Chen S, Zhu J, Xu X, Li R, Li J, Chen S, Yang X, Li H. GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction. *Int J Biol Sci* 2018; **14**: 1696-1708 [PMID: 30416384 DOI: 10.7150/ijbs.27774]

11 **Kaska L**, Sledzinski T, Chomiczewska A, Dettlaff-Pokora A, Swierczynski J. Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome. *World J Gastroenterol* 2016; **22**: 8698-8719 [PMID: 27818587 DOI: 10.3748/wjg.v22.i39.8698]

12 **Ren M**, Zhang H, Qi J, Hu A, Jiang Q, Hou Y, Feng Q, Ojo O, Wang X. An Almond-Based Low Carbohydrate Diet Improves Depression and Glycometabolism in Patients with Type 2 Diabetes through Modulating Gut Microbiota and GLP-1: A Randomized Controlled Trial. *Nutrients* 2020; **12** [PMID: 33022991 DOI: 10.3390/nu12103036]

13 **Stenman LK**, Waget A, Garret C, Briand F, Burcelin R, Sulpice T, Lahtinen S. Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice. *Diabetol Metab Syndr* 2015; **7**: 75 [PMID: 26366205 DOI: 10.1186/s13098-015-0075-7]

14 **Houlden A**, Goldrick M, Brough D, Vizi ES, Lénárt N, Martinecz B, Roberts IS, Denes A. Brain injury induces specific changes in the caecal microbiota of mice via altered autonomic activity and mucoprotein production. *Brain Behav Immun* 2016; **57**: 10-20 [PMID: 27060191 DOI: 10.1016/j.bbi.2016.04.003]

15 **Bliss ES**, Whiteside E. The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity. *Front Physiol* 2018; **9**: 900 [PMID: 30050464 DOI: 10.3389/fphys.2018.00900]

16 **Jackson A**, Forsyth CB, Shaikh M, Voigt RM, Engen PA, Ramirez V, Keshavarzian A. Diet in Parkinson's Disease: Critical Role for the Microbiome. *Front Neurol* 2019; **10**: 1245 [PMID: 31920905 DOI: 10.3389/fneur.2019.01245]

17 **Hernández MAG**, Canfora EE, Jocken JWE, Blaak EE. The Short-Chain Fatty Acid Acetate in Body Weight Control and Insulin Sensitivity. *Nutrients* 2019; **11** [PMID: 31426593 DOI: 10.3390/nu11081943]

18 **Vuik F**, Dicksved J, Lam SY, Fuhler GM, van der Laan L, van de Winkel A, Konstantinov SR, Spaander M, Peppelenbosch MP, Engstrand L, Kuipers EJ. Composition of the mucosa-associated microbiota along the entire gastrointestinal tract of human individuals. *United European Gastroenterol J* 2019; **7**: 897-907 [PMID: 31428414 DOI: 10.1177/2050640619852255]

19 **Nagpal R**, Neth BJ, Wang S, Craft S, Yadav H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment. *EBioMedicine* 2019; **47**: 529-542 [PMID: 31477562 DOI: 10.1016/j.ebiom.2019.08.032]

20 **Anderson JR**, Carroll I, Azcarate-Peril MA, Rochette AD, Heinberg LJ, Peat C, Steffen K, Manderino LM, Mitchell J, Gunstad J. A preliminary examination of gut microbiota, sleep, and cognitive flexibility in healthy older adults. *Sleep Med* 2017; **38**: 104-107 [PMID: 29031742 DOI: 10.1016/j.sleep.2017.07.018]

21 **Zhang Y**, Chen T, Zhang Y, Hu Q, Wang X, Chang H, Mao JH, Snijders AM, Xia Y. Contribution of trace element exposure to gestational diabetes mellitus through disturbing the gut microbiome. *Environ Int* 2021; **153**: 106520 [PMID: 33774496 DOI: 10.1016/j.envint.2021.106520]

22 **Ma S**, You Y, Huang L, Long S, Zhang J, Guo C, Zhang N, Wu X, Xiao Y, Tan H. Alterations in Gut Microbiota of Gestational Diabetes Patients During the First Trimester of Pregnancy. *Front Cell Infect Microbiol* 2020; **10**: 58 [PMID: 32175285 DOI: 10.3389/fcimb.2020.00058]

23 **Su Y**, Wang HK, Gan XP, Chen L, Cao YN, Cheng DC, Zhang DY, Liu WY, Li FF, Xu XM. Alterations of gut microbiota in gestational diabetes patients during the second trimester of pregnancy in the Shanghai Han population. *J Transl Med* 2021; **19**: 366 [PMID: 34446048 DOI: 10.1186/s12967-021-03040-9]

24 **Mokkala K**, Houttu N, Vahlberg T, Munukka E, Rönnemaa T, Laitinen K. Gut microbiota aberrations precede diagnosis of gestational diabetes mellitus. *Acta Diabetol* 2017; **54**: 1147-1149 [PMID: 28980079 DOI: 10.1007/s00592-017-1056-0]

25 **Kuang YS**, Lu JH, Li SH, Li JH, Yuan MY, He JR, Chen NN, Xiao WQ, Shen SY, Qiu L, Wu YF, Hu CY, Wu YY, Li WD, Chen QZ, Deng HW, Papasian CJ, Xia HM, Qiu X. Connections between the human gut microbiome and gestational diabetes mellitus. *Gigascience* 2017; **6**: 1-12 [PMID: 28873967 DOI: 10.1093/gigascience/gix058]

26 **Liu H**, Pan LL, Lv S, Yang Q, Zhang H, Chen W, Lv Z, Sun J. Alterations of Gut Microbiota and Blood Lipidome in Gestational Diabetes Mellitus With Hyperlipidemia. *Front Physiol* 2019; **10**: 1015 [PMID: 31447702 DOI: 10.3389/fphys.2019.01015]

27 **Wickens KL**, Barthow CA, Murphy R, Abels PR, Maude RM, Stone PR, Mitchell EA, Stanley TV, Purdie GL, Kang JM, Hood FE, Rowden JL, Barnes PK, Fitzharris PF, Crane J. Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. *Br J Nutr* 2017; **117**: 804-813 [PMID: 28367765 DOI: 10.1017/s0007114517000289]

28 **Laitinen K**, Poussa T, Isolauri E. Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: A randomised controlled trial.  *Br J Nutr* 2009; **101**: 1679-1687 [PMID: DOI: 10.1017/s0007114508111461]

29 **Crusell MKW**, Hansen TH, Nielsen T, Allin KH, Rühlemann MC, Damm P, Vestergaard H, Rørbye C, Jørgensen NR, Christiansen OB, Heinsen FA, Franke A, Hansen T, Lauenborg J, Pedersen O. Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum. *Microbiome* 2018; **6**: 89 [PMID: 29764499 DOI: 10.1186/s40168-018-0472-x]

30 **Huthmacher JA**, Meier JJ, Nauck MA. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis. *Diabetes Care* 2020; **43**: 2303-2312 [PMID: 32910778 DOI: 10.2337/dc20-0498]

31 **Wang Z**, Saha S, Van Horn S, Thomas E, Traini C, Sathe G, Rajpal DK, Brown JR. Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects. *Endocrinol Diabetes Metab* 2018; **1**: e00009 [PMID: 30815546 DOI: 10.1002/edm2.9]

32 **Ferrocino I**, Ponzo V, Gambino R, Zarovska A, Leone F, Monzeglio C, Goitre I, Rosato R, Romano A, Grassi G, Broglio F, Cassader M, Cocolin L, Bo S. Changes in the gut microbiota composition during pregnancy in patients with gestational diabetes mellitus (GDM). *Sci Rep* 2018; **8**: 12216 [PMID: 30111822 DOI: 10.1038/s41598-018-30735-9]

33 **Yao Y**, Yan L, Chen H, Wu N, Wang W, Wang D. Cyclocarya paliurus polysaccharides alleviate type 2 diabetic symptoms by modulating gut microbiota and short-chain fatty acids. *Phytomedicine* 2020; **77**: 153268 [PMID: 32663709 DOI: 10.1016/j.phymed.2020.153268]

34 **Fouré M**, Dugardin C, Foligné B, Hance P, Cadalen T, Delcourt A, Taminiau B, Daube G, Ravallec R, Cudennec B, Hilbert JL, Lucau-Danila A. Chicory Roots for Prebiotics and Appetite Regulation: A Pilot Study in Mice. *J Agric Food Chem* 2018; **66**: 6439-6449 [PMID: 29873488 DOI: 10.1021/acs.jafc.8b01055]

35 **Zhao D**, Zhu H, Gao F, Qian Z, Mao W, Yin Y, Tan J, Chen D. Antidiabetic effects of selenium-enriched Bifidobacterium longum DD98 in type 2 diabetes model of mice. *Food Funct* 2020; **11**: 6528-6541 [PMID: 32638790 DOI: 10.1039/d0fo00180e]

**Footnotes**

**Institutional review board statement:** The study was approved and carried out in accordance with the guidelines of the Ethics Committee of Nanhai District People’s Hospital of Foshan.

**Conflict-of-interest statement:** The authors declare that no competing interest exists.

**Data sharing statement:** Illumina sequencing reads were uploaded to the SRA under accession number PRJNA11381. The rest of the data that support the conclusions of this study are available from the corresponding author upon request.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 26, 2022

**First decision:** June 11, 2022

**Article in press:** August 24, 2022

**Specialty type:** Microbiology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Houri H, Iran; Janvilisri T, Thailand **S-Editor:** Chen YL **L-Editor:** Wang TQ **P-Editor:** Chen YX

**Figure Legends**

图表, 旭日形

描述已自动生成

**Figure 1 Operational taxonomic units distributions.** A: Species tree and distribution of the gut microbial community; B: Venn diagram showing the common or specific operational taxonomic units between the groups. NGT: Normal glucose tolerance; GDM: Gestational diabetes mellitus.

图示

描述已自动生成

**Figure 2 Gut microbiota alpha and beta diversity indices in patients with gestational diabetes mellitus.** A: Gut microbiota alpha diversity indices in patients with gestational diabetes mellitus. The Observed\_species, ACE, Chao1, Simpson, Shannon, and J values are shown; B: Principal component analysis score plot based on the relative abundance of operational taxonomic units (97% similarity levels); C: Principal coordinate analysis; D: Similarities analysis; E: Non-metric multidimensional scaling. NGT: Normal glucose tolerance; GDM: Gestational diabetes mellitus; PCoA: Principal coordinate analysis; PCA: Principal component analysis.

手机屏幕截图

中度可信度描述已自动生成

**Figure 3** **Taxonomy.** A: Top eight abundant species at the phylum level; B: Different bacteria were compared between each group at the phylum level. NGT: Normal glucose tolerance; GDM: Gestational diabetes mellitus.

图示

描述已自动生成

**Figure 4 LEfSE analysis to determine which bacterial taxa differ significantly between the groups.** A: At the family level, a greater number of different families were identified between the normal glucose tolerance (NGT) and gestational diabetes mellitus groups (GDM); B: The bacterial taxa whose levels differed significantly between the NGT and GDM groups were identified by LEfSE analysis. NGT: Normal glucose tolerance; GDM: Gestational diabetes mellitus; LDA: Linear discriminant analysis.

图表

描述已自动生成

**Figure 5** **Bacterial genera exhibit significant differences between the two groups.** A: Heatmap showing the relative total abundance of the first 30 genera; B: Microbial community at the genus level between groups. a*P* <0.05, GDM group compared with NGT group. NGT: Normal glucose tolerance; GDM: Gestational diabetes mellitus.

日程表

描述已自动生成

**Figure 6** **KEGG pathways and COG categories between the GDM and NGT groups.** A: KEGG pathway; B: COG categories. NGT: Normal glucose tolerance; GDM: Gestational diabetes mellitus.

图片包含 图示

描述已自动生成

**Figure 7 Spearman’s correlations between different dominant genera and blood biochemical traits.** a*P* <0.05, b*P* <0.01. GDM: Gestational diabetes mellitus; GLP-1: Glucagon-like peptide-1; GSP: Glycosylated serum protein; Glu: Glucose; HbA1c: Hemoglobin A1c; UA: Uric acid; TCH: Total cholesterol; TG: Triglyceride; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; INS: Insulin; OGTT: Oral glucose tolerance test; TSH: Thyroid-stimulating hormone; FT4: Free tetraiodothyronine.

图表, 散点图

描述已自动生成

**Figure 8** **Gut microbiota–based prediction of gestational diabetes mellitus.** A: Identification of gestational diabetes mellitus (GDM) markers by random forest models; B: Receiver operating characteristic (ROC) curves of operational taxonomic units-based diagnostic biomarkers for GDM. NGT: Normal glucose tolerance; GDM: Gestational diabetes mellitus; INS: Insulin; Glu: Glucose; HbA1c: Hemoglobin A1c; GLP-1: Glucagon-like peptide-1.

**Table 1 Clinical variables of gestational diabetes mellitus patients and healthy controls**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Control (25)** | **GDM (31)** | ***P* value** |
| Age (yr) | 28.42 (3.11) | 30.18 (3.26) | 0.055 |
| Pre-body weight (kg) | 52.42 (7.68) | 55.18 (6.48) | 0.165 |
| Height (cm) | 160.13 (5.44) | 157.88 (4.10) | 0.063 |
| Pre-BMI | 20.73 (2.85) | 22.2 (2.37) | 0.054 |
| GLU (mmol/L) | 4.49 (0.38) | 5.77 (0.95) | 3.53 × 10-7 |
| GLP-1 0 h (ug/L) | 67.72 (22.89) | 75.45(23.23) | 0.223 |
| GLP-1 1 h (ug/L) | 75.33 (26.14) | 84.34 (19.84) | 0.099 |
| GLP-1 2 h (ug/L) | 71.75 (23.83) | 79.21 (24.20) | 0.312 |
| OGTT 0 h (mmol/L) | 4.47 (0.39) | 5.74 (0.99) | 3.53 × 10-7 |
| OGTT 1 h (mmol/L) | 7.77 (1.55) | 11.23 (2.95) | 3.00 × 10-6 |
| OGTT 2 h (mmol/L) | 6.26 (0.87) | 9.64 (3.12) | 3.96 × 10-6 |
| Insulin 0 h (uIU/mL) | 9.78 (3.41) | 14.03 (15.93) | 0.239 |
| Insulin 1 h (uIU/mL) | 85.85 (43.99) | 64.52 (39.67) | 0.061 |
| Insulin 2 h (uIU/mL ) | 57.51 (39.36) | 66.52 (45.21) | 0.675 |
| GSP (mmol/L) | 1.68 (0.35) | 1.97 (0.62) | 0.054 |
| HbA1c (%) | 5.04 (0.30) | 5.79 (1.12) | 0.003 |
| UA (umol/L) | 279.52(68.47) | 263.80(81.27) | 0.463 |
| TCH (mmol/L) | 5.40 (1.06) | 5.35 (1.08) | 0.993 |
| TG (mmol/L) | 1.82 (0.72) | 2.45 (1.54) | 0.051 |
| HDL (mmol/L) | 2.11 (0.52) | 2.08 (0.63) | 0.946 |
| LDL (mmol/L) | 2.41 (0.89) | 2.34 (0.82) | 0.739 |
| TSH (uIU/mL) | 1.82 (3.43) | 1.22 (1.24) | 0.337 |
| FT4 (pg/mL) | 11.39 (3.27) | 11.77 (1.96) | 0.598 |

OGTT: Oral glucose tolerance test; GDM: Gestational diabetes mellitus; GLP-1: Glucagon-like peptide-1; Glu: Glucose; GSP: Glycosylated serum protein; HbA1c: Hemoglobin A1c; UA: Uric acid; TCH: Total cholesterol; TG: Triglyceride; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; TSH: Thyroid-stimulating hormone; FT4: Free tetraiodothyronine.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**